Literature DB >> 28493102

MEN2 Syndrome-Related Medullary Thyroid Carcinoma with Focal Tyrosine Hydroxylase Expression: Does It Represent a Hybrid Cellular Phenotype or Functional State of Tumor Cells?

Ozgur Mete1,2,3, Ahmed Essa4, Anil Bramdev4, Navendren Govender5, Runjan Chetty6,7.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28493102     DOI: 10.1007/s12022-017-9485-4

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


× No keyword cloud information.
  4 in total

Review 1.  Characterisation of thyroid medullary carcinoma TT cell line.

Authors:  M Zabel; J Grzeszkowiak
Journal:  Histol Histopathol       Date:  1997-01       Impact factor: 2.303

2.  Immunocytochemical characterization of two thyroid medullary carcinoma cell lines in vitro.

Authors:  M Zabel; J Seidel; A Kaczmarek; J Surdyk-Zasada; J Grzeszkowiak; A Górny
Journal:  Histochem J       Date:  1995-11

Review 3.  Algorithmic approach to neuroendocrine tumors in targeted biopsies: Practical applications of immunohistochemical markers.

Authors:  Kai Duan; Ozgur Mete
Journal:  Cancer Cytopathol       Date:  2016-08-16       Impact factor: 5.284

4.  Protocol for the examination of specimens from patients with pheochromocytomas and extra-adrenal paragangliomas.

Authors:  Ozgur Mete; Arthur S Tischler; Ronald de Krijger; Anne Marie McNicol; Graeme Eisenhofer; Karel Pacak; Shereen Ezzat; Sylvia L Asa
Journal:  Arch Pathol Lab Med       Date:  2014-02       Impact factor: 5.534

  4 in total
  2 in total

Review 1.  Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.

Authors:  Ozgur Mete; Sylvia L Asa; Anthony J Gill; Noriko Kimura; Ronald R de Krijger; Arthur Tischler
Journal:  Endocr Pathol       Date:  2022-03-13       Impact factor: 3.943

Review 2.  Immunohistochemical Biomarkers in Thyroid Pathology.

Authors:  Zubair Baloch; Ozgur Mete; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.